ReMedys is a not-for-profit, patient-centric foundation specializing in developing innovative therapeutic approaches for patients with severe disease without effective treatment – independent of commercial potential. To serve this goal, ReMedys is open to the following:
- Repurposing of existing drugs based on investigator driven research
- Development of de-prioritized, commercially unattractive projects
- Investigating early stage, innovative therapeutic approaches.
Projects may be small chemical entities, biologics or devices designed to help and provide relief to patients. All projects within the portfolio are fundable, needed and desired by patients, and attractive to doctors and patient organizations.
Academic research and start-ups continually discovers new treatment options for patients, but often lack the time, resources, ability, or know-how to bring them to the clinical trial stage.
On the other hand, pharmaceutical industry and investors prefer investing in drugs with established preclinical and early clinical safety and their interest in innovative therapeutics is, as a rule, proportional to commercial prospects rather than patient needs.
ReMedys bridges this gap between academic institutional capability and industrial requirements by providing comprehensive drug development expertise, including manufacturing, clinical development, regulatory affairs, preclinical safety, project management and unique funding opportunities through its not-for-profit status and expert network.
What We Do
ReMedys is dedicated to helping academia and biotech transform innovative therapeutic ideas into drugs, which are accessible to patients in need. ReMedys secures funding, sets up development plans and executes regulatory preclinical studies and early clinical trials.
We work in partnership with the originators to bridge the gap between innovation and clinical proof-of-concept. While our partners continue to strengthen the therapeutic approach through preclinical research, ReMedys ensures state-of-the art development capabilities through a broad network of highly qualified industry experts.
We add value to projects and reduce their risk to compel the public, investors and/or the pharmaceutical industry to invest in late stage development activities. By building the scientific know-how into the project and sharing this knowledge with our partners, we raise awareness of the demands and limitations of drug development, allowing our partners to better design their research strategy.
Remedys' Operational Model
& Funding Model
|Key Incentives for our Partners||